ASCO 2025: Cell Therapy Abstract Highlights
Our ASCO 2025 Post-Conference Report offers an in-depth analysis and summary of the 95 cell therapy-related abstracts presented at the 2025 ASCO Annual Meeting.
This report is an essential resource for staying updated on the latest developments and innovations in the field of Cell Therapy
Highlights include insights into:
- Therapeutic Class: CAR T cells remained dominant, but there was greater diversity in cell types and non-genetic engineering strategies compared to last year.
- Top Targets: CD19 was the most common disclosed target, with increased focus on B7-H3, alongside emerging targets like CD5
- Disease Breakdown: Lung Cancer was the most popular disease indication, followed by lymphoma, leukemia, ovarian cancer, and skin cancer
- Abstract Summaries for Clinical and Preclinical assets
We hope you find this report valuable and insightful and are as excited as we are to see the latest cell therapy development.
You May Also Be Interested In…
Learn More About Cell Therapy
- The Most Comprehensive Way to Search the Cell Therapy Development Landscape: Unique search ontologies based on Cell Therapy drug and trial characteristics
- Market Leading Approach to Cell Therapy Preclinical & Clinical Data Curation: Manual curation of key Cell Therapy research and development data points by Cell Therapy research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Cell Therapy company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
